GSK’s Strategy in Emerging Markets: Scale, Diversification and Access
This article was originally published in PharmAsia News
Executive Summary
Branded products are key to emerging markets, where they tend to have long lifecycles that extend well beyond patent expiration, GlaxoSmithKline's president of emerging markets Abbas Hussain told investors at a Sanford F. Bernstein conference May 6
You may also be interested in...
Egyptian Drug Price Reform: New Trade Barrier Or Demand Driver?
The new drug pricing regime, a streamlined registration process and the government's initiative to widen health insurance coverage, could help drive up domestic demand for pharmaceutical products, especially for branded generics.
Egyptian Drug Price Reform: New Trade Barrier Or Demand Driver?
The new drug pricing regime, a streamlined registration process and the government's initiative to widen health insurance coverage, could help drive up domestic demand for pharmaceutical products, especially for branded generics.
Egyptian Drug Price Reform: New Trade Barrier Or Demand Driver?
Egypt, an emerging pharmaceutical market, is implementing a series of healthcare and drug pricing reforms. The new drug pricing regime, a streamlined registration process and the government's initiative to widen health insurance coverage, could help drive up domestic demand for pharmaceutical products, especially for branded generics in the country